Cargando…

ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma

PAI-1 plays significant roles in cancer occurrence, relapse and multidrug resistance and is highly expressed in tumours. ACT001, which is currently in phase I clinical trials for the treatment of glioblastoma (GBM). However, the detailed molecular mechanism of ACT001 is still unclear. In this study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xi, Xiaonan, Liu, Ning, Wang, Qianqian, Chu, Yahui, Yin, Zheng, Ding, Yahui, Lu, Yaxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779874/
https://www.ncbi.nlm.nih.gov/pubmed/31591377
http://dx.doi.org/10.1038/s41419-019-1986-2

Ejemplares similares